Clinical Trial

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies
Trial Details
NCT Number NCT06737081
Lead Sponsor Shenzhen Salubris Pharmaceuticals Co., Ltd.
Conditions Anemia
Enrollment 60 participants
Start Date 2024-09-14
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-17